Search for: "Cooper v. Pfizer, Inc" Results 1 - 20 of 47
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
13 Jul 2021, 10:58 am by Simon Lester
In the United States (US), as for most developed countries,[6] trade policy and IP standards have consistently been linked, a pattern which can (at least partially) be traced back to extensive lobbying by senior management at US-based technology and pharmaceutical firms.[7] For example, since at least the 1980s, Pfizer Inc. has been involved in mobilizing other US firms and stakeholders to lobby US policymakers on the issue of international IP protection. [read post]
15 Dec 2016, 2:17 pm by Paul Lyons
The largest single healthcare fraud case this year—in which Wyeth and Pfizer Inc. paid $784.6 million for illegally pricing drugs for Medicaid—was initiated by two whistleblowers. [read post]
31 Oct 2016, 5:01 am by Mark Astarita
With insider trading law up in the air after the Second Circuit decision in US v. [read post]
18 Jul 2014, 11:55 am
Pfizer, Inc., 716 F.3d 1087, 1092-93 (8th Cir. 2013). [read post]
29 May 2014, 5:00 am
Abbott Labs, Inc., 444 F.3d 383, 387-88 (5th Cir. 2006), and Melder v. [read post]
22 May 2014, 5:00 am
Pfizer, Inc., 2000 WL 1099884, at *2 & n.1 (S.D.N.Y. [read post]
18 Sep 2013, 7:28 am
 The IPKat has stumbled across a decision earlier this year from the Federal Court, Canada, in Pfizer Canada Inc. v Pharmascience Inc. 2013 FC 120, dating back to 4 February. [read post]